Écrit par Pivotal | 05 Février 2019

Madrid, Spain 4 February, 2019 – Pivotal has enrolled the first patients in a recently awarded new phase II trial in Europe, testing a targeted drug in patients with von Hippel-Lindau (VHL) disease, a hereditary disease which increases the risk to develop multiple tumours, mainly renal cell cancer, and also haemangioblastoma and retinoblastoma, among others.
The...

Écrit par GOUR MEDICAL | 01 Février 2019

GOUR MEDICAL ANNONCE LE LANCEMENT D'UNE AUGMENTATION DE CAPITAL AFIN DE FINANCER LA COMMERCIALISATION DE SES PREMIERS PRODUITS A BASE DE CANNABIDIOL (CBD)

Prix de souscription unitaire : 0,80 € par action


Période de souscription : du 1er février au 8 février 2019 inclus


Augmentation de capital par placement privé avec suppression du droit préférentiel de souscription...

Écrit par GlobalData | 01 Février 2019

Amgen and Novartis had a first-mover advantage in the new class of calcitonin gene-related peptide (CGRP) migraine prevention drugs with their Aimovig (erenumab) getting FDA approval in May 2018. However, the exclusion of Aimovig by American prescription benefits manager CVS Health Corp from the list of covered drugs is a setback to its sales, says GlobalData, a leading data and analytics...

Écrit par GlobalData | 31 Janvier 2019

Although AbbVie is feeling the impact of Humira biosimilar launch in Europe, its strong immunology pipeline is likely to protect its hold on the plaque psoriasis (PsO) and rheumatoid arthritis (RA) markets, according to GlobalData, a leading data and analytics company.

According to GlobalData’s reports, ‘Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2027’ and...